PTC Therapeutics Completes Acquisition of ST-920, a One-Time AAV Gene Therapy for Fabry Disease
核心洞察
PTC Therapeutics has completed its previously announced agreement with Sangamo Therapeutics to acquire ST-920, a BLA-stage, one-time administered AAV gene therapy for Fabry disease (搜索).
A rolling BLA submission to the FDA seeking accelerated approval of ST-920 is expected to be completed in the fourth quarter of 2026.
In clinical studies, isaralgagene civaparvovec enabled long-term production of the deficient alpha-galactosidase A (搜索) enzyme and significantly reduced globotriaosylceramide levels with durable clinical benefit.
PTC Therapeutics, Inc. announced on Sept. 21, 2026 that it has completed its previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920, a BLA-stage, one-time administered AAV gene therapy for Fabry disease (搜索). The company said a rolling Biologics License Application submission to the FDA for accelerated approval of ST-920 is expected to be completed in the fourth quarter of 2026.
"Our team looks forward to completing the ST-920 BLA submission and potentially bringing a one-time administered, safe and effective durable disease treatment that addresses the limitations of chronic enzyme replacement therapy to the Fabry community," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics.
Mechanism and Clinical Findings
ST-920, also known as isaralgagene civaparvovec, is a one-time administered AAV gene therapy product candidate for the treatment of Fabry disease (搜索). According to PTC, clinical studies of isaralgagene civaparvovec enabled long-term production of the deficient alpha-galactosidase A (搜索) (α-Gal A) enzyme and a significant reduction in globotriaosylceramide (Gb3) levels, with durable clinical benefit and a reduction in the burden associated with chronic enzyme replacement therapy (ERT).
The candidate is designed to address the limitations of chronic ERT, the current chronic treatment approach referenced by the company in describing the unmet need in Fabry disease (搜索).
Regulatory Designations
Isaralgagene civaparvovec has received Orphan Drug, Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA. In Europe, the therapy has received Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency (搜索). The U.K. Medicines and Healthcare products Regulatory Agency has granted the candidate access to the Innovative Licensing and Access Pathway.
Fabry Disease Background
Fabry disease (搜索) is a lysosomal storage disorder caused by mutations in the galactosidase alpha gene (GLA). These mutations lead to deficient alpha-galactosidase A (搜索) (α-Gal A) enzyme activity, which is necessary for metabolizing globotriaosylceramide (Gb3). The buildup of Gb3 in cells can cause serious damage to vital organs, including the kidney, heart, nerves, eyes, gut and skin.
Symptoms of Fabry disease (搜索) can include decreased or absent sweat production, heat intolerance, angiokeratoma (skin blemishes), vision problems, kidney disease, heart failure, gastrointestinal disturbance, mood disorders, neuropathic pain and tingling in the extremities.
Development Outlook
PTC noted that, as with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products, and that there are no guarantees that any product will receive or maintain regulatory approval in any territory or prove to be commercially successful. The company's forward-looking statements regarding ST-920 include expectations about the anticipated benefits of the therapy and the timing of and potential for regulatory submissions and a potential commercial launch.